Evidence map›Paper›PMID 32202936›Full record

ReviewCirculation2020

Research Priorities for Heart Failure With Preserved Ejection Fraction: National Heart, Lung, and Blood Institute Working Group Summary.

Sanjiv J Shah, Barry A Borlaug, Dalane W Kitzman, Andrew D McCulloch, Burns C Blaxall, Rajiv Agarwal, Julio A Chirinos, Sheila Collins, Rahul C Deo, Mark T Gladwin and 8 more

2 registry-linked trialsOpen access · bronzeAbstract readReview
In one paragraph

Review in Circulation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 263 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
263citing papers in PubMed, 6 pooled it
35.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05486000 narecruitingnot on this mapstarted 2022, after this paper: background citation

Evaluating the Safety and Efficacy of Atrial Shunt Implantation Systems for the Treatment of Patients With Chronic Left Heart Failure Prospective, Multicenter, Single-group Target Value Clinical Trials

TypeinterventionalSponsorMorningside (Nantong) Medical Co.,LtdRan2022 to 2026Enrolled120ConditionsLeft Heart FailureArmsAtrial shunt implant system
NCT05784753 narecruitingnot on this mapstarted 2023, after this paper: background citation

HEART (Heart Failure Exercise and Resistance Training) Camp Connect: Promoting Adherence to Exercise in Adults With Heart Failure With Preserved Ejection Fraction

TypeinterventionalSponsorUniversity of NebraskaRan2023 to 2028Enrolled300ConditionsHFpEF - Heart Failure With Preserved Ejection FractionArmsHEART Camp, HEART Camp Connect
3 · Its place in the literature

Who cites it

263 citing papers in PubMed, 6 syntheses or guidelines pooled it, 396 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Guideline
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Article
  14. The Intersection of Heart Failure with Preserved Ejection Fraction and CKD.Clinical journal of the American Society of Nephrology : CJASN · 2026
    Review
  15. Article
  16. Review
  17. Which heart failure phenotypes benefit from GLP-1 receptor agonists?Cardiovascular diabetology. Endocrinology reports · 2026
    Article
  18. Review
  19. Targeting PKGIα CysScience advances · 2026
    Article
  20. Article

203 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 2 institutions in 1 country.

Sanjiv J ShahNorthwestern University Feinberg School of Medicine, Chicago, IL (S.J.S.).
Barry A BorlaugMayo Clinic, Rochester, MN (B.A.B., M.M.R.).
Dalane W KitzmanWake Forest School of Medicine, Winston-Salem, NC (D.W.K.).
Andrew D McCullochUniversity of California, San Diego (A.D.M.).
Burns C BlaxallChrist Hospital Health Network, Cincinnati, OH (B.C.B.).
Rajiv AgarwalIndiana University, Indianapolis (R.A.).
Julio A ChirinosUniversity of Pennsylvania, Philadelphia (J.A.C.).
Sheila CollinsVanderbilt University, Nashville, TN (S.C., T.J.W.).
Rahul C DeoBrigham and Women's Hospital, Boston, MA (R.C.D).
Mark T GladwinUniversity of Pittsburgh, PA (M.T.G.).
Henk GranzierUniversity of Arizona, Tucson (H.G.).
Scott L HummelUniversity of Michigan and the Ann Arbor Veterans Affairs Health System (S.L.H.).
David A KassJohns Hopkins University, Baltimore, MD (D.A.K.).
Margaret M RedfieldMayo Clinic, Rochester, MN (B.A.B., M.M.R.).
Flora SamBoston University School of Medicine, MA (F.S.).
Thomas J WangVanderbilt University, Nashville, TN (S.C., T.J.W.).
Patrice Desvigne-NickensNational Heart, Lung, and Blood Institute, National Institute of Health, Bethesda, MD (P.D.-N., B.B.A.).
Bishow B AdhikariNational Heart, Lung, and Blood Institute, National Institute of Health, Bethesda, MD (P.D.-N., B.B.A.).
Northwestern University · USUniversity of Pennsylvania · US

Funding

Wake Forest Claude D. Pepper OAIC - RenewalP30AG021332 · NIA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI Jamie Nicole Justice · 2002 to 2026
$36.4M
Subclinical Vascular Contributions to Alzheimer's Disease: The Multi-Ethnic Study of Atherosclerosis (MESA) Multisite Study of AD (Renewal)R01AG058969 · NIA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI Timothy M. Hughes, YONGMEI LIU · 2018 to 2026
$33.4M
Vascular Subphenotypes of Lung DiseaseP01HL103455 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI GLADWIN, MARK T · 2011 to 2020
$26.1M
Understanding the relationship between obesity and tongue fat in humans and ratsP01HL094307 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI PACK, ALLAN I · 2009 to 2020
$23.7M
Vanderbilt Clinical Oncology Research Career Development ProgramK12CA090625 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Debra L. Friedman, Paula Jill Hurley · 2001 to 2026
$16.9M
Storage Lesion in Banked Blood Due to Disruption of Nitric Oxide HomeostasisR01HL098032 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Mark T Gladwin · 2009 to 2026
$12.5M
Proteomics CoreP50DK096418 · NIDDK · CINCINNATI CHILDRENS HOSP MED CTR · PI DEVARAJAN, PRASAD · 2012 to 2021
$8.4M
Antidote for inhaled CO poisoning based on mutationally engineered neuroglobinR01HL125886 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Mark T Gladwin, Jesus Tejero Bravo · 2015 to 2026
$7.9M
REHAB-HF: A Trial of Rehabilitation Therapy in Older Acute Heart Failure PatientsR01AG045551 · NIA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI KITZMAN, DALANE W · 2014 to 2018
$6.8M
Transition from Risk Factors to Early HF: Prevalence, Pathogenesis, and PhenomicsR01HL127028 · NHLBI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI BERTONI, ALAIN GERALD, SHAH, SANJIV J · 2015 to 2018
$6.5M
Leveraging Protein Kinase G-1 Nanodomain Control and Molecular Targeting to Enhance its Therapeutic Use Against Myocardial DiseaseR35HL135827 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI KASS, DAVID ALAN · 2017 to 2023
$6.3M
Intraosseous delivery of lentiviral vectors for hemophilia A gene therapyR01HL134321 · NHLBI · SEATTLE CHILDREN'S HOSPITAL · PI Carol H Miao · 2016 to 2026
$6.2M
NCI NIH HHS K12 CA090625NHLBI NIH HHS DP2 HL123228NHLBI NIH HHS P01 HL094307NHLBI NIH HHS P01 HL103455NHLBI NIH HHS R01 HL098032NHLBI NIH HHS R01 HL104106NHLBI NIH HHS R01 HL107577NHLBI NIH HHS R01 HL117153NHLBI NIH HHS R01 HL118524NHLBI NIH HHS R01 HL121510NHLBI NIH HHS R01 HL125886NHLBI NIH HHS R01 HL126638NHLBI NIH HHS R01 HL127028NHLBI NIH HHS R01 HL128526NHLBI NIH HHS R01 HL132551NHLBI NIH HHS R01 HL133695NHLBI NIH HHS R01 HL134321NHLBI NIH HHS R01 HL140731NHLBI NIH HHS R01 HL144657NHLBI NIH HHS R01 HL149423NHLBI NIH HHS R35 HL135827NHLBI NIH HHS R56 HL136730NHLBI NIH HHS R61 HL146390NHLBI NIH HHS T32 HL110849NHLBI NIH HHS U01 HL125175NHLBI NIH HHS U01 HL125205NHLBI NIH HHS U10 HL110262NIA NIH HHS P30 AG021332NIA NIH HHS R01 AG018915NIA NIH HHS R01 AG045551NIA NIH HHS R01 AG058969NIA NIH HHS U24 AG059624NIDDK NIH HHS P50 DK096418NIDDK NIH HHS R01 DK103056
6 · The paper itself

Abstract

Heart failure with preserved ejection fraction (HFpEF), a major public health problem that is rising in prevalence, is associated with high morbidity and mortality and is considered to be the greatest unmet need in cardiovascular medicine today because of a general lack of effective treatments. To address this challenging syndrome, the National Heart, Lung, and Blood Institute convened a working group made up of experts in HFpEF and novel research methodologies to discuss research gaps and to prioritize research directions over the next decade. Here, we summarize the discussion of the working group, followed by key recommendations for future research priorities. There was uniform recognition that HFpEF is a highly integrated, multiorgan, systemic disorder requiring a multipronged investigative approach in both humans and animal models to improve understanding of mechanisms and treatment of HFpEF. It was recognized that advances in the understanding of basic mechanisms and the roles of inflammation, macrovascular and microvascular dysfunction, fibrosis, and tissue remodeling are needed and ideally would be obtained from (1) improved animal models, including large animal models, which incorporate the effects of aging and associated comorbid conditions; (2) repositories of deeply phenotyped physiological data and human tissue, made accessible to researchers to enhance collaboration and research advances; and (3) novel research methods that take advantage of computational advances and multiscale modeling for the analysis of complex, high-density data across multiple domains. The working group emphasized the need for interactions among basic, translational, clinical, and epidemiological scientists and across organ systems and cell types, leveraging different areas or research focus, and between research centers. A network of collaborative centers to accelerate basic, translational, and clinical research of pathobiological mechanisms and treatment strategies in HFpEF was discussed as an example of a strategy to advance research progress. This resource would facilitate comprehensive, deep phenotyping of a multicenter HFpEF patient cohort with standardized protocols and a robust biorepository. The research priorities outlined in this document are meant to stimulate scientific advances in HFpEF by providing a road map for future collaborative investigations among a diverse group of scientists across multiple domains.

Indexed as

Heart FailureHumansNational Heart, Lung, and Blood Institute (U.S.)ResearchStroke VolumeUnited Statesdiagnosisheart failureprecision medicinetherapeutics

Identifiers

PMID32202936
PMCPMC7101072
OpenAlexW3012616651

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.